#ACTIV5

Interesting preprint of the #LIVEAIR study of #lenzilumab in #COVID19:-double blind RCT n=502 hospitalized pts on suppl O2-lenzilumab associated with improved survival w/o ventilation: 84% vs 77.9% -larger benefit when